Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, a clinical-stage biopharmaceutical company specializing in iPSC-derived cellular immunotherapies, announced it awarded restricted stock units totaling 67,300 shares to two newly-hired non-executive employees as an inducement to join the company. The RSUs will vest over four years. This action follows Nasdaq Listing Rule 5635(c)(4…